Myriad Genetics announced that the United States Patent and Trademark Office has issued a second patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease, MRD, assay to market. U.S. patent no. 12,024,749, entitled “Combinatorial DNA Screening,” covers Myriad’s groundbreaking platform MRD technology, which enables highly sensitive and specific tumor-informed, sequencing-based MRD assays such as Precise MRD. Specifically, the patented method relates to detecting circulating tumor DNA in patient fluid samples, including blood and plasma.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Myriad Genetics Earns 2024 Great Place To Work® Certification™
- Scotiabank starts Myriad Genetics with Outperform amid transformation
- Myriad Genetics initiated with an Outperform at Scotiabank
- Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election